NEW YORK (GenomeWeb News) – Clinical lab organizations and a number of companies that develop and make molecular diagnostics have banded together to create a group to press for better government reimbursement while the US Centers for Medicare and Medicaid Services works to restructure its pricing plans.

The Coalition to Strengthen the Future of Molecular Diagnostics said last week that it has launched because CMS has been paying lower reimbursement rates while it conducts a review of its process for pricing these tests.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.